We examined the responses to chemoradiation according to imaging modality in limited-stage small-cell lung cancer (SCLC). Provided patients achieved at least a partial response, advanced imaging response neither affected survival nor added information to the decision to offer prophylactic cranial irradiation (PCI), suggesting that limited-stage SCLC patients with partial response using any imaging modality should not be denied PCI. Introduction: Prophylactic cranial irradiation (PCI) improves survival for small-cell lung cancer (SCLC). Evidence for PCI in limited-stage SCLC largely derives from studies requiring only chest x-ray (CXR) to determine remission status. We analyzed thoracic chemoradiation therapy (TCRT) outcomes according to imaging modality to determine which patients benefitted most from PCI. Patients and Methods: All limited-stage SCLC patients who received TCRT as well as PCI at our institution were reviewed. Imaging between TCRT end and PCI start was characterized as complete (CR), partial (PR), or other response. Results: Thirty-eight consecutive patients were assessed for TCRT response before PCI with CXR (n ¼ 21), chest computed tomography (CT; n ¼ 27), and/or positron emission tomography (PET)/ CT (n ¼ 11). CR was identified on 71% of CXRs, 41% of CT scans, and 18% of PET/CT scans. Median survival was 28.3 months for the entire cohort and did not differ for patients who had CXR alone versus CT and/or PET/CT for restaging (P ¼ .78) or those with PR using any modality versus CR using all modalities (22.6 months vs. 45.5 months; P ¼ .22). CT CR patients had numerical but not statistically significant improved 2-year (P ¼ .18) and 3-year (P ¼ .13) survival compared with CT PR. Conclusion: CXR remains an appropriate modality to assess TCRT response before PCI in limited-stage SCLC. Advanced imaging did not inform the decision to offer PCI in this study. Because of similar excellent survival profiles independent of imaging modality and TCRT response, this analysis suggests limited-stage SCLC patients with PR using any modality should not be denied PCI, akin to standards for extensive-stage SCLC.
Introduction
Small-cell lung cancer (SCLC) is considered a systemic disease with a high rate of distant dissemination, including to the brain. Approximately 10% to 15% of patients with SCLC are diagnosed with brain metastasis, and 30% to 60% develop intracranial metastasis during the course of their illness.
At diagnosis, approximately one-third of patients with SCLC are found to have limited-stage disease without extrathoracic metastases. Radiation therapy administered concurrently with cisplatin and etoposide is standard treatment for patients with limited-stage SCLC. [3] [4] [5] Thoracic chemoradiation therapy (TCRT) allows for up to a 90% response rate, with 50% to 80% of limited-stage SCLC patients achieving a complete response (CR) to therapy. [6] [7] [8] However, platinum-based chemotherapy does not effectively cross the bloodebrain barrier, leaving the central nervous system vulnerable to subsequent metastases. In fact, approximately 50% to 80% of patients who achieve a CR to initial therapy will develop brain metastasis within 2 years, with the risk increasing with a longer survival from diagnosis. 9, 10 Prophylactic cranial irradiation (PCI) has been shown to decrease the development of brain metastasis and improve disease-free as well as overall survival in extensive-stage patients, but no similar survival benefit has been shown in a prospective study for limited-stage patients. 1, 11 An Institut Gustave-Roussy study randomized 300
patients with predominantly limited-stage SCLC who achieved a CR to chemoradiation to receive PCI versus no PCI. Although PCI reduced the overall rate of brain metastasis (40% vs. 67%; P < .00001), even in an expansion analysis of 511 patients they did not find a significant improvement in overall survival (18% vs. 15% at 5 years; P ¼ .06). 1, 12 Two meta-analyses have shown an overall survival benefit to PCI in limited-stage patients, 11, 13 but an early presentation of a phase III randomized trial failed to show a benefit of PCI in this population.
14 Unlike with extensive-stage SCLC, PCI trials for limited-stage SCLC have generally only included patients who have achieved a CR to initial therapy. However, previous published studies and meta-analyses, such as the Prophylactic Cranial Irradiation Overview Collaboration Group meta-analysis, 11 have often required only a chest x-ray (CXR) to assess response status. Consequently, many patients classified as having a CR on CXR might have been classified as having a more limited response to TCRT had they undergone more advanced imaging studies, such as computed tomography (CT) imaging of the chest or positron emission tomography (PET)/ CT imaging, 15 and they accordingly would not have been offered PCI or been eligible for these previous trials despite the potential for PCI to improve survival in this population. 11 Additionally, current practice guidelines dictate CT imaging to assess for thoracic treatment response before considering PCI. 16 In this study, we analyzed and defined thoracic responses to TCRT according to imaging modality for patients with limitedstage SCLC to determine which imaging modality most correlates with overall survival and which patients benefit most from PCI. We hypothesized that fewer patients would have a CR on advanced imaging compared with CXR, and that patients with a CR on CXR or a partial response (PR) or CR on advanced imaging would have prolonged survival that would warrant proceeding with PCI, whereas survival would be inferior in patients with a PR on CXR.
Patients and Methods
In this institutional review board-approved study, all patients with histologically-confirmed limited-stage SCLC who received thoracic radiation therapy as well as concurrent chemotherapy followed by PCI at the University of Pennsylvania from 1998 to 2010 were reviewed to allow for adequate duration of follow-up to assess for survival outcomes. Patients who received any component of treatment of thoracic radiotherapy, chemotherapy, or PCI at another facility were excluded from this analysis. All patients were treated with definitive-intent thoracic radiotherapy delivered either once or twice daily with concurrent platinum-based chemotherapy. In all cases, radiation therapy began with either cycle 1 or cycle 2 of chemotherapy. PCI was delivered within 6 months of initiating chemotherapy and within 3 to 12 weeks after completing chemotherapy.
All patients underwent imaging with at least 1 radiologic modality (CXR, CT of the chest, and/or PET/CT imaging) to assess thoracic disease response of the primary tumor as well as sites of nodal metastases after the completion of TCRT but before beginning PCI. All CXRs were ordered and conducted with a posteroanterior as well as a lateral approach. All patients also underwent neuroimaging, most commonly with magnetic resonance imaging, but when not possible CT with intravenous contrast imaging, between the completion of TCRT and the start of PCI to confirm the absence of brain metastases. Each imaging study between the end of TCRT and the start of PCI was characterized as a CR, PR, stable disease, or disease progression. CXR and CT images were characterized according to modified Response Evaluation Criteria in Solid Tumors criteria on the basis of reports from board-certified radiologists who specialize in thoracic imaging. 17 CR was defined as the total resolution of all parenchymal disease and a reduction of all lymph nodes to <1.0 cm in short axis. PR was defined as a 30% decrease in the sum of the diameters of all target lesions. Progressive disease was defined as a 20% increase in the sum of the diameters of lesions or the appearance of new lesions, whereas stable disease was defined as neither sufficient shrinkage to quality for PR nor sufficient increase to qualify for progressive disease. Positron emission tomography was characterized according to Positron Emission Tomography Response Criteria in Solid Tumors 1.0. 18 CR was defined as resolution of fluorodeoxyglucose (FDG) uptake, with FDG uptake less than the mean standardized uptake value corrected for lean body mass (SUL) of the liver, but designation of CR did not require the peak SUL to decrease to 0. PR was defined as a decrease of 30% and 0.8 SUL units in the most intense lesion between baseline and follow-up. Progressive disease was defined as an increase of 20% and of 0.8 SUL units in a target lesion or development of new lesions, whereas stable disease was defined as an increase or decrease of peak SUL of <30%.
Overall survival was calculated from the date of PCI start to the date of patient death or last contact. Two-way unpaired t tests were used to determine significance between groups and statistical significance was defined as P < .05.
Results
Thirty-eight consecutive patients were included. Patients were predominantly female (76%) and Caucasian (84%), with a median age of 66 years at the time of PCI (Table 1) . Patients received once (n ¼ 4, median 63 Gy in 1.8 Gy fractions) or twice (n ¼ 34, median 45 Gy in 1.5 Gy fractions) daily thoracic radiation therapy concurrent with platinum-based chemotherapy, most frequently for 4 cycles (89%). PCI began at a median of 11.4 weeks after the completion of thoracic radiation therapy and was most commonly
Advanced Imaging in Assessing Response Before PCI in LS-SCLC administered to 25 Gy in 2.5 Gy twice daily fractions (n ¼ 17) (range, 24-36 Gy in 1.5-2.5 Gy fractions). After TCRT, patients underwent CXR (n ¼ 21), CT of the chest (n ¼ 27), and/or PET/ CT imaging (n ¼ 11) for restaging before PCI.
All patients had either a CR or PR to TCRT that was confirmed on all imaging modalities obtained, with no patient included in this analysis with identified disease progression or stable disease. Concordance in classifying treatment response in patients with more than 1 imaging modality was 65% ( Table 2 ). All discordances were for patients classified as having CRs on CXR who were found to have PRs on CT imaging of the chest (overall CXR-CT chest concordance 57%; n ¼ 14) or PET/CT imaging (overall CXR-PET/CT concordance 83%; n ¼ 6), and 1 patient with a CR on CT imaging of the chest but PR on PET/CT imaging (overall CT chest-PET/CT imaging concordance, 67%; n ¼ 3).
A CR that was identified on reimaging before PCI was significantly more likely to be reported on CXR (71%) than advanced imaging (34%; CT of the chest, 41%; PET/CT, 18%; P ¼ .006). All remaining studies showed a PR to TCRT. Although only 18% (n ¼ 2 of 11) of patients were found to have a CR on PET/CT imaging just before PCI, 60% (n ¼ 3 of 5) of the remaining patients who had a subsequent repeat PET/CT scan a median of 3 months after completion of TCRT that were classified as initially having a PR on the pre-PCI PET/CT scan were found to have a CR on subsequent PET/CT imaging without receiving any additional systemic or thoracic therapy.
Median survival was 28.3 months for the entire cohort and 45.1 months for patients alive at the time of censorship (n ¼ 17). Across modalities and responses, patients with PRs on CXR (25.5 months) and PET/CT imaging (22.6 months) had the lowest median survival (Table 3) . Patients with a CR on CT of the chest had numerically but not statistically significant improvement in 1-year (91% vs. 69%; P ¼ .19), 2-year (82% vs. 56%; P ¼ .18), and 3-year (55% vs. 25%; P ¼ .13) overall survival compared with those with a PR on CT imaging of the chest. CR versus PR did not correlate with survival on either CXR (median 30.0 months vs. 25.5 months) or PET/CT imaging (median 25.5 months vs. 22.6 months; P > .05 for both). Survival did not differ on the basis of whether patients underwent CXR reimaging alone of if they underwent an advanced reimaging modality with CT and/or PET/CT imaging (P ¼ .78). Furthermore, a CR on any one imaging modality did not show improved survival over a CR on any other imaging modality. Patients with a CR on all sampled modalities had numerically but not statistically significantly longer median survival (45.2 months vs. 22.6 months; P ¼ .22) and 2-year overall survival (71% vs. 48%; P ¼ .17) compared with those found to have a PR on any modality, but this trend was lost with more extended followup ( Figure 1 ).
Discussion
This study shows similar overall survival for patients with limitedstage SCLC restaged before PCI with CXR, CT of the chest, or PET/CT imaging. Significantly fewer patients were found to have a CR on advanced imaging (CT of the chest or PET/CT) than on CXR. In this study we also found that FDG uptake can persist for >12 weeks from TCRT completion, even in patients with a CR on 
Aparna H. Kesarwala et al
Clinical Lung Cancer March 2018 -e207
CT of the chest who might ultimately achieve a CR on subsequent PET/CT imaging. This study also showed that although patients with CRs on all imaging modalities tended to live longer than those with a PR on any modality, high survival rates were achieved in this study even for patients with PRs on CXRs and advanced imaging studies.
A meta-analysis of nearly 2000 SCLC patients from 16 randomized trials from the past 30 years offers insight into which patients might benefit most from PCI. 13 There was a 4.4% reduction in overall mortality in patients who received PCI compared with those randomized not to receive PCI, with the benefits of PCI greatest among patients obtaining a CR after induction therapy (P ¼ .02) and no survival benefit among patients who failed to respond to therapy (P ¼ .29).
Whereas most studies have focused on patients receiving PCI after a CR to chemotherapy, a recent Canadian meta-analysis investigated the effect of PCI on SCLC patients with incomplete responses to chemoradiation. 19 Of the 93 patients who were incomplete responders, brain metastases occurred in 6.1% of patients who received PCI and 27.6% in those who did not receive PCI, indicating significant benefits of PCI even among incomplete responders. This analysis did allow for CT evaluation of response, however, so patients considered incomplete responders might have been classified as having a CR had they only been evaluated with a CXR, which was generally the only reimaging modality used in previous trials. This benefit among patients not achieving a CR is in keeping with our findings that high rates of survival were seen in our cohort that were similar among CR and PR patients. As such, there is rationale for the consideration of PCI for all patients with limitedstage SCLC who respond to TCRT.
We acknowledge that the current study has several limitations. First, we had a limited patient sample size and not all patients received each of the different types of imaging modalities for assessment before PCI. These facts might have limited our ability to detect a difference in survival between patients achieving a CR and PR to TCRT, as well as limited our ability to definitively determine the concordance rates between imaging modalities for limited-stage SCLC. The findings of this retrospective study should be confirmed with data from larger, prospective series, such as the recently reported concurrent once-daily versus twice-daily radiotherapy (CONVERT) trial 20 or the currently accruing CALGB (Cancer and Leukemia Group B) 30610/RTOG 0538 trial. Regarding our discordance rates, CRs were more likely to be reported on CXR than CT imaging. We believe this to be a reflection of the decreased resolution and sensitivity of CXR compared with CT imaging, as well as the potential for increased post-TCRT pulmonary changes to be interpreted as residual disease on CT or PET/CT imaging. Additionally, we only evaluated patients who completed definitive TCRT as well as PCI at our institution, which meant that we did not evaluate nonresponders or patients whose disease progressed on TCRT nor those found to have new brain metastases at the time of restaging neuroimaging. The survival numbers we present in this study are superior to most reports for limited-stage SCLC, which is likely in part due to selection bias. Our patient sample set also had a disproportionate number of women, who have better associated survival, leading to potential confounding gender disparities in our study cohort. Additionally, because of the largely uniform timing of initiation of PCI after TCRT, we were not able to assess whether timing of these restaging studies and PCI delivery had an effect on outcome.
Previous phase II and III trials for limited-stage SCLC reported high CR þ PR overall response rates of approximately 80% to 95%, 6, 7, 21 whereas our cohort only included patients who responded to TCRT. We were therefore not able to determine if or how PCI would have benefitted patients who had either progressive or stable disease after TCRT and how advanced imaging response assessment should be used in these patients. As such, additional investigation is needed to compare patients who respond versus do not respond to initial therapy, although we hypothesize that the benefit of PCI is likely to be more limited in nonresponders. Furthermore, our analysis was limited to patients treated with 
Conclusion
Very few data are available on treatment response to TCRT for limited-stage SCLC on the basis of advanced imaging modalities such as CT or PET/CT, and it is not currently known how a PR on advanced imaging influences overall survival nor how this should affect the decision to administer PCI. Provided patients achieved at least a PR to TCRT, advanced imaging did not add information to assist in the decision to offer PCI compared with CXR alone, and CXR remains an appropriate modality to assess response to TCRT before PCI. PET/CT restaging before PCI might be of limited utility because TCRT response on early PET/CT imaging did not predict for survival. Furthermore, FDG uptake can persist for >12 weeks from the completion of TCRT, even in patients with a CR on CT of the chest who might ultimately achieve a CR on subsequent PET/CT imaging. Because of the similar and high rates of survival independent of imaging modality and TCRT response, this study suggests that limitedstage SCLC patients with a PR on any modality should not be denied PCI, akin to current standards for patients with extensive-stage SCLC.
Clinical Practice Points
Prophylactic cranial irradiation administered to SCLC patients without evidence of intracranial metastases has been shown to reduce the development of brain metastases and improve overall survival. Previously published studies of PCI have generally required only a CXR to assess response to TCRT. Consequently, the response of patients who underwent more advanced imaging studies, such as CT or PET/CT, might have been classified as more limited than if they had undergone CXR. They would then not have been offered PCI in trials that required patients to have a thoracic CR to be eligible for PCI. In this study, we analyzed and defined responses to TCRT according to imaging modality for limited-stage SCLC patients. Provided patients achieved at least a PR to TCRT, we found that advanced imaging response neither affected survival nor added information to assist in the decision to offer PCI. Our findings suggest that limited-stage SCLC patients with a PR on any imaging modality should not be denied PCI, akin to current standards for patients with extensive-stage SCLC.
